Jessa B. Castillo

University of California, San Francisco — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index173citations74works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(35), Glioma Diagnosis and Treatment(31), 3D Printing in Biomedical Research(17), ATP Synthase and ATPases Research(16), Radiomics and Machine Learning in Medical Imaging(12)

Publications74 total

Development of [18F]RP115 for clinical imaging of EAAT2 in neurodegenerative diseases
Nuclear Medicine and Biology·2025Open Access
Optimisation of Manufacturing and Quality Control Processes of Radiopharmaceuticals After First-in-Human Studies
Nuclear Medicine and Biology·2025Open Access
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDG
Journal of Nuclear Medicine·2024· 27 citedOpen Access
A Practical Guide to Sigma-1 Receptor Positron Emission Tomography/Magnetic Resonance Imaging: A New Clinical Molecular Imaging Method to Identify Peripheral Pain Generators in Patients with Chronic Pain
Seminars in Musculoskeletal Radiology·2023· 3 citedOpen Access
Synthesis of [18F]FAraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms
Nuclear Medicine and Biology·2023
Development and Initial Assessment of [18F]OP-801: a Novel Hydroxyl Dendrimer PET Tracer for Preclinical Imaging of Innate Immune Activation in the Whole Body and Brain
Molecular Imaging and Biology·2023· 5 cited
Development and initial assessment of [18F]OP-801: a novel hydroxyl dendrimer PET tracer for preclinical imaging of innate immune activation in the whole body and brain
Research Square (Research Square)·2023Open Access
Supplementary Table from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Data from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Figure from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Table from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Figure from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Data from &lt;sup&gt;89&lt;/sup&gt;Zr-panitumumab Combined With &lt;sup&gt;18&lt;/sup&gt;F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Figure S6 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Figure S1 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Table S4 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Table S4 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Table S5 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
Supplementary Table S6 from A Clinical PET Imaging Tracer ([&lt;sup&gt;18&lt;/sup&gt;F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Mary Ellen I. Koran(29), Andrei Iagaru(29), Samantha T. Reyes(27), Michelle L. James(26), Jun Hyung Park(25), Israt S. Alam(25), Bin Shen(24), Mehdi Khalighi(23), Corinne Beinat(23), Tom Haywood(23), Sanjiv S. Gambhir(23), Surya Murty(22), Lewis Naya(22), Megan Phillips(22), Pablo Buccino(22), Dawn Holley(22), Kim Halbert(22), Harsh Gandhi(22), Joy Q. He(22), Monica Granucci(22)